MA37676A1 - Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation - Google Patents
Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisationInfo
- Publication number
- MA37676A1 MA37676A1 MA37676A MA37676A MA37676A1 MA 37676 A1 MA37676 A1 MA 37676A1 MA 37676 A MA37676 A MA 37676A MA 37676 A MA37676 A MA 37676A MA 37676 A1 MA37676 A1 MA 37676A1
- Authority
- MA
- Morocco
- Prior art keywords
- rebamipid
- prodrug
- manufacturing process
- manufacture
- new prodrug
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 4
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 208000007882 Gastritis Diseases 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000023652 chronic gastritis Diseases 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne un nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation, et, de façon plus spécifique, un nouveau promédicament de rebamipide, son procédé de fabrication et une composition pharmaceutique le contenant comme principe actif. Le nouveau promédicament de rebamipide selon la présente invention a une vitesse d'absorption dans le corps d'approximativement 25 fois la vitesse d'absorption du rebamipide, et ainsi peut être utilisé de façon efficace, à la place du rebamipide, dans la prévention ou le traitement de l'ulcère gastrique, de la gastrite aiguë et chronique, du syndrome de sécheresse oculaire, du cancer, de l'arthrose, de la polyarthrite rhumatoïde ou de l'obésité.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120068394 | 2012-06-26 | ||
| PCT/KR2013/005622 WO2014003424A1 (fr) | 2012-06-26 | 2013-06-26 | Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37676A1 true MA37676A1 (fr) | 2016-10-31 |
| MA37676B1 MA37676B1 (fr) | 2017-07-31 |
Family
ID=49783488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37676A MA37676B1 (fr) | 2012-06-26 | 2013-06-26 | Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11420963B2 (fr) |
| EP (1) | EP2865669B1 (fr) |
| JP (1) | JP6032451B2 (fr) |
| KR (1) | KR101452277B1 (fr) |
| CN (1) | CN104662004B (fr) |
| AP (1) | AP2015008233A0 (fr) |
| AR (1) | AR097226A1 (fr) |
| AU (1) | AU2013281442B2 (fr) |
| BR (1) | BR112014032627A8 (fr) |
| CA (1) | CA2877853C (fr) |
| CL (1) | CL2014003496A1 (fr) |
| CO (1) | CO7240352A2 (fr) |
| ES (1) | ES2875863T3 (fr) |
| IL (1) | IL236479A0 (fr) |
| MA (1) | MA37676B1 (fr) |
| MX (1) | MX2015000023A (fr) |
| NZ (1) | NZ704023A (fr) |
| PE (2) | PE20160285A1 (fr) |
| PH (1) | PH12015500172A1 (fr) |
| RU (1) | RU2612509C2 (fr) |
| SA (1) | SA113340675B1 (fr) |
| SG (1) | SG11201408711PA (fr) |
| TW (1) | TWI483727B (fr) |
| UA (1) | UA113990C2 (fr) |
| UY (1) | UY34882A (fr) |
| WO (1) | WO2014003424A1 (fr) |
| ZA (1) | ZA201500450B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| WO2016108319A1 (fr) * | 2015-01-02 | 2016-07-07 | 삼진제약 주식회사 | Nouveau sel de promédicament du rébamipide et son utilisation |
| KR20170094584A (ko) * | 2016-02-11 | 2017-08-21 | 삼진제약주식회사 | 레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물 |
| KR102190019B1 (ko) * | 2018-10-23 | 2020-12-15 | 삼진제약주식회사 | 쇼그렌 증후군 예방 또는 치료용 조성물 |
| EP3797773A1 (fr) * | 2019-09-03 | 2021-03-31 | Square Power Ltd | Rebamipide destiné à être utilisé dans la prévention et le traitement du cancer |
| ES2913792T3 (es) * | 2019-09-03 | 2022-06-06 | Square Power Ltd | Rebamipida para uso en la profilaxis y el tratamiento de la enfermedad celíaca |
| CN111595985B (zh) * | 2020-07-09 | 2022-03-29 | 苏州正济药业有限公司 | 一种用hplc测定瑞巴派特有关物质的分析方法 |
| WO2024224086A1 (fr) | 2023-04-27 | 2024-10-31 | Imhotex Limited | Diacides de desmuramylpeptides en tant qu'agonistes de nod2 et leur utilisation |
| WO2024224093A1 (fr) | 2023-04-27 | 2024-10-31 | Imhotex Limited | Diesters de desmuramylpeptides en tant qu'agonistes de nod2 et leur utilisation |
| EP4750753A1 (fr) * | 2023-07-26 | 2026-06-03 | Supernus Pharmaceuticals, Inc. | Dérivés substitués d'isoindoles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI80022C (fi) | 1982-07-05 | 1990-04-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat. |
| JPS6019767A (ja) * | 1983-07-11 | 1985-01-31 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体を有効成分とする抗潰瘍剤 |
| JP3621463B2 (ja) * | 1995-04-26 | 2005-02-16 | 大塚製薬株式会社 | カルボスチリル誘導体ビスマス塩 |
| KR100669823B1 (ko) | 2001-02-20 | 2007-01-17 | 경동제약 주식회사 | 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체 |
| EP1336602A1 (fr) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Prodrogues nitrées capable de libérer du monoxyde d'azote de manière controlée et sélective ainsi que leur utilisation pour la prévention et le traitement de maladies inflammatoires, ischémiques et proliferatives |
| KR20040104020A (ko) | 2003-06-02 | 2004-12-10 | 진양제약주식회사 | 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제 |
| TWI363626B (en) * | 2004-11-15 | 2012-05-11 | Otsuka Pharma Co Ltd | Aqueous ophthalmic suspension of crystalline rebamipide |
| WO2006059781A1 (fr) | 2004-12-01 | 2006-06-08 | Otsuka Pharmaceutical Co., Ltd. | Procédé amélioré de synthèse du rebamipide |
| JP2008105970A (ja) | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | ジヒドロキノリン誘導体の製造方法及びその中間体 |
| WO2008074853A1 (fr) | 2006-12-21 | 2008-06-26 | Novartis Ag | Solution ophtalmique de rebamipide |
| KR101032600B1 (ko) | 2008-08-11 | 2011-05-06 | 동우신테크 주식회사 | 고순도 레바미피드의 제조방법 |
| KR101182114B1 (ko) | 2010-03-05 | 2012-09-12 | 한림제약(주) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 |
| CN102174015B (zh) | 2011-03-07 | 2013-10-16 | 江西同和药业有限责任公司 | 瑞巴派特的精制方法 |
-
2013
- 2013-06-24 SA SA113340675A patent/SA113340675B1/ar unknown
- 2013-06-26 AR ARP130102268A patent/AR097226A1/es unknown
- 2013-06-26 MX MX2015000023A patent/MX2015000023A/es unknown
- 2013-06-26 RU RU2015102043A patent/RU2612509C2/ru active
- 2013-06-26 MA MA37676A patent/MA37676B1/fr unknown
- 2013-06-26 JP JP2015520012A patent/JP6032451B2/ja not_active Expired - Fee Related
- 2013-06-26 PE PE2016000265A patent/PE20160285A1/es unknown
- 2013-06-26 US US14/411,390 patent/US11420963B2/en active Active
- 2013-06-26 EP EP13809037.8A patent/EP2865669B1/fr active Active
- 2013-06-26 KR KR1020130073535A patent/KR101452277B1/ko not_active Expired - Fee Related
- 2013-06-26 SG SG11201408711PA patent/SG11201408711PA/en unknown
- 2013-06-26 AU AU2013281442A patent/AU2013281442B2/en not_active Ceased
- 2013-06-26 NZ NZ704023A patent/NZ704023A/en not_active IP Right Cessation
- 2013-06-26 WO PCT/KR2013/005622 patent/WO2014003424A1/fr not_active Ceased
- 2013-06-26 PE PE2014002534A patent/PE20150904A1/es not_active Application Discontinuation
- 2013-06-26 UY UY0001034882A patent/UY34882A/es not_active Application Discontinuation
- 2013-06-26 CN CN201380034373.4A patent/CN104662004B/zh not_active Expired - Fee Related
- 2013-06-26 BR BR112014032627A patent/BR112014032627A8/pt not_active Application Discontinuation
- 2013-06-26 ES ES13809037T patent/ES2875863T3/es active Active
- 2013-06-26 TW TW102122678A patent/TWI483727B/zh not_active IP Right Cessation
- 2013-06-26 CA CA2877853A patent/CA2877853C/fr active Active
- 2013-06-26 UA UAA201500494A patent/UA113990C2/uk unknown
- 2013-06-26 AP AP2015008233A patent/AP2015008233A0/xx unknown
-
2014
- 2014-12-22 CL CL2014003496A patent/CL2014003496A1/es unknown
- 2014-12-25 IL IL236479A patent/IL236479A0/en unknown
-
2015
- 2015-01-22 ZA ZA2015/00450A patent/ZA201500450B/en unknown
- 2015-01-26 PH PH12015500172A patent/PH12015500172A1/en unknown
- 2015-01-26 CO CO15014548A patent/CO7240352A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37676B1 (fr) | Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation | |
| FR25C1042I1 (fr) | Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 | |
| WO2013112950A3 (fr) | Entités chimiques particulières, compositions et procédés | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA40283A (fr) | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations | |
| MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
| EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| NZ702414A (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
| EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
| BR112015026307A2 (pt) | heterociclo bicíclicos como inibidores de fgfr | |
| FR2985274B1 (fr) | Structures fibreuses comprenant des particules et leur procede de fabrication | |
| EA201390409A1 (ru) | Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием | |
| CA2929436C (fr) | Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires | |
| EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
| MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| MX2016005668A (es) | Formas cristalinas de compuestos terapeuticos y sus usos. | |
| FR2972456B1 (fr) | Pigments traites hydrophiles dispersibles dans une composition cosmetique | |
| FR3029790B1 (fr) | Microbille d'hydrogel de chitosane | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
| MX2018003975A (es) | Combinacion de glicosaminoglicanos y un agente antacido y sus composiciones. | |
| MA20150279A1 (fr) | (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel | |
| EP2572721A4 (fr) | Composition pharmaceutique comprenant un inhibiteur de hif-2 comme ingrédient actif pour la prévention ou le traitement de l'arthrite | |
| EA201491691A1 (ru) | Агрегаты наночастиц, содержащие остеопонтин и кальций- и/или стронцийсодержащие частицы | |
| MA35457B1 (fr) | Nouvelles formulations de pyriméthanil et leur utilisations dans le traitement des cultures |